Project Grant HT9425261E295
- Federal Grant Award Summary The University of California, San Francisco (UCSF) received a $1,594,419 Project Grant award from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) for the project "Radiopathomic Mapping of Tumor Burden for Personalized Management of IDH-Mutant Glioma." The award, effective September 1, 2025, through August 31, 2028, supports advanced biomedical research focused on developing innovative diagnostic and...
- Federal Grant Award Summary The University of California, San Francisco (UCSF) received a $1,054,812 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) effective August 15, 2026, through August 14, 2030. This award supports biochemical and structural targeting research focused on GAQ-mutant melanoma, a specific melanoma subtype. The research initiative will be conducted at UCSF's San Francisco facility and represents the...
- Federal Grant Award Summary The University of California, San Francisco (UCSF) received a $1.148 million Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) for the period September 1, 2025, through August 31, 2028. The award funds research focused on "Targeting and Imaging Vitamin B5 Metabolism in Diffuse Midline Gliomas," a three-year biomedical research initiative designed to advance understanding of metabolic...
- Federal Project Grant Award Summary The University of California, San Francisco (UCSF) received a $328,000 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), effective July 1, 2025, through June 30, 2027. The award funds research on intracranial drug delivery strategies targeting skull bone marrow to generate antitumoral myeloid cell immune responses against glioblastoma. This research initiative represents UCSF's...
- Federal Project Grant Award Summary The University of California, San Francisco (UCSF) received a $1,620,505 project grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), effective June 1, 2026, through May 31, 2029. The award supports research and development services focused on novel mitochondrial metabolism inhibitors for aggressive and treatment-resistant MYC-high breast cancers. The research will be conducted at UCSF's San Francisco,...
- Federal Grant Award Summary The University of California, San Francisco (UCSF) received a $1,226,730 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), effective August 1, 2025, through July 31, 2029. The award funds research investigating the canonical Polycomb Repressive Complex 1 (cPRC1) as an intrinsic mechanism of resistance to enzalutamide in advanced prostate cancer. This hypothesis-driven research initiative...
- Federal Project Grant Award Summary The University of California, San Francisco (UCSF) received a $2.72 million Project Grant award from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), effective July 15, 2025, through July 14, 2029. The award supports advanced biomedical research titled "Imaging Cardiac Metabolic Flux and Mitochondrial Function by Hyperpolarized 13C and CEST Metabolic Magnetic Resonance Imaging," which will...
- Federal Project Grant Award Summary The University of California, San Francisco (UCSF) received a $1.23 million Project Grant award from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) on September 30, 2025, with a completion date of September 29, 2029. The award supports research to validate CD46 as a promising biomarker in advanced prostate cancer, aligning with the DHA's mission to transform healthcare for service members and the...
- Federal Grant Award Summary The University of California, San Francisco (UCSF) received a $865,284 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), effective August 15, 2026, through August 14, 2030. The grant supports research focused on biochemical and structural targeting of GAQ-mutant melanoma, a specific melanoma subtype. This award reflects the Defense Health Agency's commitment to advancing innovative...
- Federal Grant Award Summary The University of California, San Francisco (UCSF) received a $1,257,982 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) awarded August 1, 2025, with a completion date of July 31, 2028. The project, titled "Mapping the RNA Splicing Landscape of NF1 and Its Impact on Neurofibromin Function Across Tissues," supports advanced biomedical research focused on understanding RNA...
The University of California, San Francisco (UCSF) received a $1.4 million Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) effective July 1, 2026, through July 31, 2029. The award supports research investigating metabolic mechanisms of resistance to mutant isocitrate dehydrogenase (IDH) inhibition in gliomas. This hypothesis-driven biomedical research initiative aligns with the DHA's broader mission to transform healthcare for service members and the American public through innovative medical solutions addressing critical health challenges, with particular emphasis on oncology and precision medicine therapeutics. Under this three-year award, UCSF will deliver basic and translational research services focused on understanding how glioma tumors develop resistance mechanisms to mutant IDH-targeted therapies. The research outputs will include biomarker discovery, mechanistic characterization of metabolic pathways, and potential therapeutic insights applicable to glioma treatment optimization. Performance will be conducted at UCSF's San Francisco facility, leveraging the institution's established capabilities in cancer research, translational medicine, and molecular biology to support the Defense Health Agency's research priorities.Federal Project Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $1.4m | 6/10/26 |